Ivantis Loses Bid to Contest Glaukos Patent on Eye-Stent Device

Ivantis didn’t meet its burden to show it was likely to win the argument that Glaukos patent 6,626,858 is invalid, Patent Trial and Appeal Board said in decision on its electronic docket.

• PTAB declines to institute review of Glaukos patent
• Patent is related to Glaukos’ iStent Inject product, which reduces pressure in the eyes of patients with glaucoma
• Ivantis filed petition April 12 to have patent canceled; Glaukos sued Ivantis two days later in California, alleging infringement of two patents, including the ‘858 patent
  • The California case is pending
  • PTAB already had denied two petitions to review the other patent ...